You are here


Member Since 2021

Bob Ragusa

Chief Executive Officer

Bob Ragusa is the Chief Executive Officer of GRAIL. Bob was previously Chief Operations Officer for Illumina where he was responsible for the company’s operations serving clinical and research customers. His organization included the global Manufacturing, Clinical Lab Services, Supply Chain, Quality, Life Cycle Management, Information Technology, and Global Facilities and Real Estate teams.

Prior to joining Illumina, Bob was Executive Vice President of Engineering and Global Operations at Accuray, a radiation oncology company, where he and his team were responsible for the development, manufacturing and distribution of innovative precision treatment solutions. Bob served as Senior Vice President of Global Operations for Applied Biosystems from 1997 until 2005.

Bob currently serves on the Board of Directors for Twist Biosciences. He holds a Bachelor of Science in Electrical Engineering and a Master of Business Administration from the University of Connecticut as well as a Master of Science in Biomedical and Electrical Engineering from Carnegie Mellon University.


GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on saving lives and improving health by pioneering new technologies for early cancer detection. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine’s greatest challenges with Galleri™, GRAIL’s multi-cancer early detection blood test. With this proprietary technology, GRAIL is also developing solutions to help accelerate cancer diagnoses, blood-based detection for minimal residual disease, and other post-diagnostic applications. GRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. Learn more: